Dialybrid srl is a newly established start-up whose aim is to continue and complete the development of a proprietary technology in arteriovenous vascular grafts for haemodialysis.
The company has in fact created SAG, a semi-resorbable vascular prosthesis that gradually integrates into the body of haemodialysis patients, thanks to the hybrid nature of the Silkothane® material with which it is made.
Thanks to the simultaneous presence of fibroin and polyurethane, and its three-layer architecture subject to patent application, SAG combines the advantages of common synthetic grafts (possibility of early cannulation) and those of native arteriovenous fistulas (good rates of long-term patency). Its technology would allow access to haemodialysis even for those patients who need urgent dialysis or who are not candidates for the implantation of a native fistula, eliminating possible rejections.
The peculiarity of SAG consists in being able to be potentially used (cannulated and connected to the dialysis machine) immediately after the implantation like the common synthetic “grafts”, but, unlike them, over time it is remodelled and integrated by the host organism, getting to resemble a native vase. This solution leverages the elastic and mechanical properties of polyurethane and the high degree of biocompatibility of the organic component made up of silk fibroin, combined in the innovative Silkothane® material.